燃小安_甲基化_全身体检_癌症预防早检_癌症早期筛查体检项目|燃石医学官方网站

Pan-Cancer Early Detection

Clinical Trials

Early detection and treatment are important components of comprehensive cancer control. Cancer, when identified early, is more likely to respond to effective treatment, resulting in a greater probability of surviving as well as less expensive treatment.

Cancer is one of the major diseases that seriously threaten human health. 80% of cancer patients are diagnosed in middle and late stages, putting heavy economic burden on their families and society. As the population ages, it becomes even more challenging in prevention and treatment of cancer. Most early-stage cancer can be effectively treated through radical surgeries. Once cancer patients have clinically detectable metastasis, it will be difficult to be cured, and the patients

The 5-year cancer-related mortality in patients with distant metastatic cancer

79%

The 5-year cancer-related mortality in patients with localized cancer

11%

Early detection and early treatment of cancer will directly reduce the mortality and improve the overall survival of cancer patients

*http://www.caca.org.cn/system/2012/02/22/010099070.shtml

*SEER Program (www.seer.cancer.gov) *Stat Database: Incidence - SEER 18 R egs Research Data, Nov 2018

INNOVATION LEADS TO BREAKTHROUGHS

Early Detection

Capturing early signals of cancer

before clinical symptoms appear

Comprehensive Inspection

Covering 6 major cancers with high

incidence and mortality in China

Precise Positioning

Accurately identifying signals of cancer,

locating invaded organs,

and guiding the following clinical examinations

Safe and Convenient

Easy to operate, time-saving,

and efficient in detecting hidden cancer;

Non-invasive, painless, and non-radioactive

80.6%

Sensitivity

98.3%

Specificity

82%

TOO

6-cancer data released at the ESMO Asia Virtual Congress

Qiang Gao BL, Shangli Cai, et al. LBA3-Early detection and localization of multiple cancers using a blood-based methylation assay (ELSA-seq). ESMO Asia Virtual Congress 2020 (20-22 November). 2020.

Detection of cfDNA
methylation signals based
on liquid biopsy

High-throughput sequencing
covers 8,000+
methylation sites,
fully covering cancer signals

STRONG EXPERTISE

The cfDNA level in early-stage cancer patients

is low, how can we build a stable database?

BRELSA ® Technology

We have world-leading technologies to enable
high-efficiency isolation of low-volume cfDNA,
starting with 500 pg cfDNA.

There are multiple repetitive-element regions where DNA methylation occurs

how can we accurately capture it?

BRMERMAID® Software

We’ve designed a multi-layer structure for
methylation probes, which can help accurately
locate methylation in repetitive-element regions.

CLINICAL TRIALS

万人前瞻性癌症早检临床试验

(The clinical study has been approved by the China Human Genetic Resources Administration Office.)

PREDICT

Pan-canceR Early DetectIon projeCT

Leading site:Zhongshan Hospital, Fudan University

Principal investigator:Professor Fan Jia, Fellow of the Chinese Academy of Sciences and President of Shanghai Zhongshan Hospital

Cancer types covered:multiple cancers with high incidence and mortality in China, including liver cancer, lung cancer, pancreatic cancer, ovarian cancer, colorectal cancer, esophageal cancer, gastric cancer, cholangiocarcinoma, head and neck cancer, etc.

Participants:14,026 cases

Research highlights:The PREDICT study is the first prospective, blind-validated, pan-cancer early detection study in China, enrolling more than 10,000 participants . The study has for the first time comprehensively explored cfDNA methylation, together with serum tumor markers and blood RNA. The study will optimize and evaluate the sensitivity, specificity and TOO of cfDNA methylation-based pan-cancer early detection in patients with multiple cancers.

(The clinical study has been approved by the China Human Genetic Resources Administration Office.)

PRESCIENT

Pan-canceR Early-Stage deteCtion by lIquid biopsy tEchNique projecT

Leading site:Cancer Hospital of the Chinese Academy of Medical Sciences

Principal investigator:Professor He Jie, Fellow of the Chinese Academy of Sciences and head of the China National Cancer Center; Professor Wang Jie

Cancer types covered:22 cancer types, including those with high incidence and mortality in China, as well as some rare cancers

Participants:11,879 cases

Research highlights:Research highlights: The PRESCIENT study is the first prospective, pan-cancer early detection study based on liquid biopsy and multi-omics technique in China, enrolling more than 10,000 participants. It is part of the National Key Research and Development Program — Research & Development and Evaluation of Liquid Biopsy Technique for Early-Stage Screening and Diagnosis of Malignant Tumors — undertaken by Cancer Hospital, Chinese Academy of Medical Sciences (project ID: 2019YFC131570). The study will promote the development of pan-cancer early detection and screening technologies in China, and will help identify the specific epigenetic characteristics of cancer patients with different etiologies and pathologies.

CLINICAL TRIAL SITES

Leading Sites